What's Happening?
Vertex Pharmaceuticals and CRISPR Therapeutics are forecasting a substantial increase in revenue for their joint gene therapy, Casgevy, in 2026. The therapy, which targets sickle cell disease and beta thalassemia, is expected to see a rise in patient infusions and insurance coverage. In 2025, Casgevy generated $115.8 million in revenue, with expectations to reach $500 million in combined revenue with Vertex's new pain medication, Journavx, in 2026. This marks a significant increase from the $10 million earned in 2024, its first full year of availability. The therapy's growth is attributed to increased patient access and insurance coverage, with 90% of U.S. patients now having reimbursed access. Additionally, Casgevy is covered in 10 countries
outside the U.S., including a recent approval in Scotland.
Why It's Important?
The projected growth of Casgevy represents a major advancement in gene therapy for sickle cell disease and beta thalassemia, conditions that have limited treatment options. The increase in revenue and patient access could lead to broader acceptance and utilization of gene therapies in the U.S. healthcare system. This growth also highlights the potential for gene therapies to become a significant revenue stream for pharmaceutical companies, encouraging further investment and innovation in the field. The expansion of insurance coverage is crucial for patient access, potentially improving outcomes for those affected by these genetic disorders.
What's Next?
Vertex plans to expand Casgevy's label to include patients aged 5 to 11, with a quick review expected due to a National Priority Review Voucher. The company is also working on increasing the number of patients receiving the therapy, which could stabilize revenue fluctuations. As more patients begin treatment, the therapy's revenue is expected to become more consistent. The continued expansion of insurance coverage and international approvals will be key factors in sustaining growth.
